Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2025-12-25 @ 2:28 AM
NCT ID:
NCT00656734
Eligibility Criteria:
Inclusion Criteria:
* Histologically confirmed diagnosis of RCC with clear cell component
* Measurable disease
* Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy
* Subjects with treated brain metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off steroids for at least 4 weeks to be eligible
* At least 28 days since the last chemotherapy
* At least 28 days before the first dose of MDX 1411 since any major surgery
* ECOG performance status 0-2
* No known positivity for human immunodeficiency virus (HIV), Hep B or C
Exclusion Criteria:
* Previous treatment with any other anti-CD70 antibody
* Active infection requiring i.v systemic therapy within 28 days before first dose
* Evidence of bleeding diathesis or coagulopathy
* Active autoimmune disease requiring immunosuppressive therapy
* Known current drug or alcohol abuse
* Any underlying medical condition which will make the administration of MDX 1411 hazardous
* Psychiatric illness or social situation that would preclude study compliance
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00656734
Study Brief:
Protocol Section:
NCT00656734